TG101209
936091-14-4
99%
2026-08-12
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Product Description
-
Seller Information
-
Description
ProductName TG101209 Cat No CEI-0194 Description As a JAK2 selective inhibitor, TG101209 can inhibit JAK2 (IC50=6 nM), FLT3 (IC50=25 nM) and RET (IC50=17 nM) kinases and JAK3 (IC50=169 nM). CAS No 936091-14-4 Molecular Weight 509.67 Purity >99% Storage 2 years at -20 centigrade Targets JAK2, FLT3, RET Molecular Formula C26H35N7O2S Chemical Name N-tert-butyl-3-(5-methyl-2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-ylamino)benzenesulfonamide Solubility DSMO 102 mg/mL Water In vitro As a JAK2 selective inhibitor, TG101209 can inhibit JAK2 (IC50=6 nM), FLT3 (IC50=25 nM) and RET (IC50=17 nM) kinases and JAK3 (IC50=169 nM). By inducing cell cycle arrest and apoptosis, and inhibiting phosphorylation of JAK2V617F, STAT5 and STAT3, TG101209 inhibit the cell proliferation of human JAK2V617F-expressing acute myeloid leukemia cell line. TG101209 inhibited growth of Ba/F3 cells expressing JAK2V617F or MPLW515L mutations with an IC50 of 200 nM.TG101209 can induce cytotoxicity in a variety of multiple myeloma (MM) cell lines in dose- and time-dependent manners. TG101209 can induce apoptosis and inhibit cell cycle progression in myeloma cell lines and patient-derived plasma cells. Co-treatment with BEZ235 and JAK2-TKI (TG101209 and SAR302503) synergistically induced lethal activity against the cultured and primary CD34+ MPN cells while relatively sparing the normal CD34+ HPCs. In vivo Treatment with TG101209 not only prevented bleomycin-induced fibrosis but also effectively reduced skin fibrosis in TSK-1 mice. addition of TG101209 to radiation in lung xenografts produced a significant tumor growth delay (>10 days) compared with radiation alone and was well tolerated. TG101209 increased apoptosis and decreased cell proliferation and vascular density. category Inhibitors(c1514) cas_num 936091-14-4 Basic Info-
Product Name:
N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide
Other Name:N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide;TG101209/TG-101209;TG101209, >=99%;N-tert-Butyl-3-[[5-methyl-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]benzenesul
CAS No.:936091-14-4
Molecular Formula:C26H35N7O2S
InChIKeys:JVDOKQYTTYUYDV-UHFFFAOYSA-N
Molecular Weight:509.67
Exact Mass:509.257294
DSSTox ID:DTXSID80587364
Categories:
Characteristics-
PSA:
111
XLogP3:4.2
Density:1.3±0.1 g/cm3
Boiling Point:703.1ºC at 760 mmHg
Flash Point:379.0±35.7 °C
Refractive Index:1.622
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Location:
Shirley, New York 11967, USA
-
Payment Terms:
TT against copy of documents,D/P
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Year of Establishment:
2004
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product